DE69924375D1 - Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms - Google Patents

Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms

Info

Publication number
DE69924375D1
DE69924375D1 DE69924375T DE69924375T DE69924375D1 DE 69924375 D1 DE69924375 D1 DE 69924375D1 DE 69924375 T DE69924375 T DE 69924375T DE 69924375 T DE69924375 T DE 69924375T DE 69924375 D1 DE69924375 D1 DE 69924375D1
Authority
DE
Germany
Prior art keywords
reizdary
norcisapride
syndrome
treatment
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69924375T
Other languages
English (en)
Other versions
DE69924375T2 (de
Inventor
D Rubin
J Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69924375D1 publication Critical patent/DE69924375D1/de
Publication of DE69924375T2 publication Critical patent/DE69924375T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
DE69924375T 1998-06-15 1999-06-10 Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms Expired - Fee Related DE69924375T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8922498P 1998-06-15 1998-06-15
US89224P 1998-06-15
US12227599P 1999-03-01 1999-03-01
US122275P 1999-03-01
PCT/US1999/013099 WO1999065571A2 (en) 1998-06-15 1999-06-10 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders

Publications (2)

Publication Number Publication Date
DE69924375D1 true DE69924375D1 (de) 2005-04-28
DE69924375T2 DE69924375T2 (de) 2005-08-11

Family

ID=26780365

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924375T Expired - Fee Related DE69924375T2 (de) 1998-06-15 1999-06-10 Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms

Country Status (26)

Country Link
US (4) US6048879A (de)
EP (1) EP1089733B1 (de)
JP (1) JP2002518352A (de)
KR (3) KR20060067986A (de)
CN (1) CN1312717A (de)
AR (1) AR019671A1 (de)
AT (1) ATE291427T1 (de)
AU (1) AU4433399A (de)
BG (1) BG105096A (de)
BR (1) BR9911299A (de)
CA (1) CA2333666A1 (de)
CZ (1) CZ20004737A3 (de)
DE (1) DE69924375T2 (de)
ES (1) ES2237110T3 (de)
HK (1) HK1040058A1 (de)
HU (1) HUP0102203A3 (de)
IL (1) IL140118A0 (de)
IS (1) IS5756A (de)
NO (1) NO20006357L (de)
NZ (3) NZ535135A (de)
PL (1) PL345275A1 (de)
PT (1) PT1089733E (de)
SI (1) SI1089733T1 (de)
SK (1) SK19052000A3 (de)
TR (7) TR200103058T2 (de)
WO (1) WO1999065571A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
HUP0102026A3 (en) 1998-06-15 2002-12-28 Sepracor Inc Marlborough Use of optically pure (-) norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimis, and other disorders
WO2000051582A2 (en) * 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1435238A1 (de) * 1999-03-01 2004-07-07 Sepracor Inc. Verfahren zur Behandlung von Apnoe und Apnoe-Erkrankungen mit optisch reinem R(+)Ondansetron
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
WO2005120363A1 (en) 2004-06-03 2005-12-22 Mayo Foundation For Medical Education And Research Obesity treatment and device
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
US7725195B2 (en) * 2006-02-16 2010-05-25 Imthera Medical, Inc. RFID-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea
CA2697822A1 (en) 2007-10-09 2009-04-16 Imthera Medical, Inc. Apparatus, system, and method for selective stimulation
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
WO2011059531A1 (en) 2009-11-10 2011-05-19 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
WO2015134747A1 (en) 2014-03-06 2015-09-11 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) * 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4598123A (en) * 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) * 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) * 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ATE170747T1 (de) * 1991-12-21 1998-09-15 Smithkline Beecham Plc Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5407953A (en) * 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
EA002362B1 (ru) * 1997-07-11 2002-04-25 Янссен Фармацевтика Н.В. Применение (+)-4-амино-5-хлор-n-(3-метокси-4-пиперидинил)-2-метоксибензамида для приготовления лекарственных препаратов для лечения заболеваний желудочно-кишечного тракта

Also Published As

Publication number Publication date
US20050154018A1 (en) 2005-07-14
TR200103058T2 (tr) 2002-06-21
ES2237110T3 (es) 2005-07-16
SI1089733T1 (en) 2005-06-30
PL345275A1 (en) 2001-12-03
NO20006357D0 (no) 2000-12-13
PT1089733E (pt) 2005-08-31
JP2002518352A (ja) 2002-06-25
ATE291427T1 (de) 2005-04-15
HK1040058A1 (zh) 2002-05-24
US6369079B1 (en) 2002-04-09
TR200103057T2 (tr) 2002-06-21
CN1312717A (zh) 2001-09-12
KR20010052739A (ko) 2001-06-25
AR019671A1 (es) 2002-03-13
EP1089733B1 (de) 2005-03-23
US6048879A (en) 2000-04-11
BR9911299A (pt) 2001-03-13
NZ508824A (en) 2003-10-31
AU4433399A (en) 2000-01-05
US20020147220A1 (en) 2002-10-10
TR200103055T2 (tr) 2002-06-21
US6835740B2 (en) 2004-12-28
KR20060067986A (ko) 2006-06-20
TR200103059T2 (tr) 2002-06-21
IL140118A0 (en) 2002-02-10
NO20006357L (no) 2001-02-13
WO1999065571A2 (en) 1999-12-23
TR200003708T2 (tr) 2001-06-21
TR200103056T2 (tr) 2002-06-21
KR20060017570A (ko) 2006-02-23
DE69924375T2 (de) 2005-08-11
TR200103054T2 (tr) 2002-06-21
NZ535135A (en) 2006-04-28
IS5756A (is) 2000-12-08
WO1999065571A3 (en) 2000-04-20
HUP0102203A3 (en) 2001-12-28
CZ20004737A3 (cs) 2001-10-17
EP1089733A2 (de) 2001-04-11
SK19052000A3 (sk) 2001-06-11
BG105096A (en) 2002-02-28
CA2333666A1 (en) 1999-12-23
NZ526943A (en) 2004-11-26
HUP0102203A2 (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69718731D1 (de) Kombinationstherapie für die Behandlung von Psychosen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69528109D1 (de) Thieno -1,5- benzodiazepin zur Behandlung gastrointestinaler Beschwerden
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69501172D1 (de) Einrichtung für die Behandlung von Substrat
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE344661T1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60001255T2 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE69924488D1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee